X
23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

0 Comments | | Return |

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

Daylight Saving Time Begins March 10

Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...

Read More >

COVID-19 Antibody Testing Frequently Asked Questions

The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...

Read More >

Reminder-MD Revised Headers on CTS forms

Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...

Read More >

FDA Releases Zika Virus (ZIKV) Guidance and Grifols ZIKV Assay Licensed

On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...

Read More >

CTS to Implement Donor HLA testing on the Stratec Gemini Instrument

On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...

Read More >

Reminder-Check flights and cargo hours for the Labor Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Subscribe here to receive CTS updates!

Name